Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Autosomal dominant intermediate Charcot-Marie-Tooth disease type F is a rare hereditary motor and sensory neuropathy disorder characterized by the typical CMT phenotype (slowly progressive distal muscle atrophy and weakness in upper and lower limbs, distal sensory loss in extremities, reduced or absent deep tendon reflexes and foot deformities) with nerve biopsy demonstrating demyelinating and axonal changes and nerve conduction velocities varying from the demyelinating to axonal range.
Features include always present findings: Onion bulb formation, Peripheral demyelination, Distal lower limb muscle weakness, and Hammertoe and others; and very common findings: Absent Achilles reflex and Absent patellar reflexes. 16 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Arms and legs | 4 | Distal upper limb muscle weakness, Distal lower limb muscle weakness, Distal upper limb amyotrophy |
GNB4 encodes G protein subunit beta 4 (340 aa). Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. Highest expression in Cells Cultured fibroblasts (43.9 TPM) and Artery Aorta (29.5 TPM).
Charcot-Marie-Tooth disease dominant intermediate F is associated with mutations in the GNB4 gene on chromosome 3.
The GNB4 protein participates in Partially folded GNB4, G-protein beta 1-4 subunit, and Partially folded G-protein beta 1-4 pathways.
GNB4 is classified as a druggable target with score 0.0.
Genetic testing for GNB4 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 5 always present features, 2 very common features, 3 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Charcot-Marie-Tooth disease dominant intermediate F.
1 publication has been identified in PubMed for Charcot-Marie-Tooth disease dominant intermediate F. Research spans Basic Science / Preclinical (100%).
Wilhelm SDP (2024). [PMID: 39352000](https://pubmed.ncbi.nlm.nih.gov/39352000/). *IUBMB life*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 1:02 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Charcot-Marie-Tooth disease dominant intermediate F
Brain and nerves | 2 | Hyporeflexia, Steppage gait |
Muscles | 2 | Distal upper limb muscle weakness, Distal lower limb muscle weakness |